تاثیر دوازده هفته تمرینات تناوبی مقاومتی همراه با مصرف مکمل جلبک آلگومد روی سطوح آسپروسین و امنتین-1 پلاسمایی در مردان چاق

فصلنامه زیست شناسی جانوری

دوره 16، شماره 2، اسفند 1402، صفحه 263-276   

نوع مقاله: مقالات پژوهشی

شناسه دیجیتال (DOI): 10.22034/ascij.2023.2002124.1564

نویسندگان

ارزو باجلانی؛ حسین عابدنطنزی^* ؛ فرشاد غزالیان

گروه تربیت بدنی و علوم ورزشی، واحد علوم و تحقیقات تهران، دانشگاه آزاد اسلامی، تهران، ایران

چکیده

چاقی از عوامل اصلی مرگ و میر در کشورهای درحال توسعه خصوصا کشور ایران است. هدف از پژوهش حاضر بررسی تاثیر 12 هفته تمرین تناوبی مقاومتی همراه با مکمل آلگومد روی آسپروسین و امنتین-1 در مردان چاق بود. 44 مرد چاق به چهار گروه 11 نفری کنترل، تمرین، مکمل و تمرین مکمل تقسیم خواهند شد. آزمودنی‌های گروه تمرین 12 هفته، هفته ای سه جلسه تمرینات تناوبی مقاومتی را انجام خواهند داد. همچنین آزمودنی‌های گروه مکمل 1800 میلی‌گرم جلبک آلگومد (کلرلا ولگاریس) را به صورت 6 قرص (2 قرص یک و نیم ساعت قبل از صبحانه، 2 قرص یک ساعت و نیم قبل از نهار، 2 قرص یک ساعت و نیم قبل از شام) (بر اساس دستور عمل کارخانه ) مصرف کردند. گروه دارونما نیز قرص­های نشاسته همرنگ قرص آلگومد مصرف کردند. 48 ساعت قبل از شروع پژوهش و 48 ساعت بعد از آخرین روز تمرین خون­گیری به عمل خواهد آمد و در نهایت شاخص­های یاد شده اندازه گیری خواهد با استفاده از کیت و دستگاه الایزا اندازه­گیری خواهد شد. نتایج پژوهش حاضر نشان داد که بین گروه­ها تفاوت معنی دار وجود دارد (05/0p < ). آزمون تعقیبی نشان داد که تمرین و تمرین مکمل باعث افزایش امنتین-1 و کاهش آسپروسین نسبت به گروه کنترل و مکمل شد (05/0p < ). نتایج حاضر نشان داد که تمرین تناوبی مقاومتی به تنهایی و همراه با مکمل­یاری کلرلا باعث کاهش سطوح أسپروسین و افزایش امنتین-1 در مردان چاق شد. همچنین مصرف کلرلا به همراه تمرین تناوبی مقاومتی در مقایسه با تمرین تناوبی مقاومتی به تنهایی دارای تاثیر بیشتری روی سطوح متغیرهای مورد بررسی بود.
 

کلیدواژه‌ها

تمرین مقاومتی؛ آلگومد؛ آدیپوکاین؛ کلرلا ولگاریس؛ چاقی

مراجع

1. Akbulut T., Cinar V., Ugur K., Yardim M., Karagoz Z., Aydin S. 2022. Effect of regular exercise on the levels of subfatin and asprosin: a trial with different types of exercise. European Review for Medical and Pharmacological Sciences, 26(8):2683-2691.
2. Balistreri C.R., Caruso C., Candore G. 2010. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators of Inflammation, 2010:802078.
3. Brzycki M. 1993. Strength testing—predicting a one-rep max from reps-to-fatigue. Journal of Physical Education, Recreation and Dance, 64(1):88-90.
4. Castro C.A., Silva K.A., Rocha M.C., Sene-Fiorese M., Nonaka K.O., Malavazi I. 2019. Exercise and omentin: their role in the crosstalk between muscle and adipose tissues in type 2 diabetes mellitus rat models. Frontiers in Physiology, 9:1881.
5. De Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z., Pray J. 2007. Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56(6):1655-1661.
6. Gerst F., Wagner R., Oquendo M.B., Siegel-Axel D., Fritsche A., Heni M. 2019. What role do fat cells play in pancreatic tissue? Molecular Metabolism, 25:1-10.
7. Gharanei S., Shabir K., Patel V., Brown J, Kyrou I., Randeva H. 2022. editors. Asprosin exerts pro-inflammatory effects via the TLR4 pathway in THP-1 macrophages. Endocrine Abstracts, 2022:86 P60.
8. Görgens S.W., Eckardt K., Jensen J., Drevon C.A., Eckel J. 2015. Exercise and regulation of adipokine and myokine production. Progress in Molecular Biology and Translational Science, 135:313-336.
9. Greulich S., Chen W.J., Maxhera B., Rijzewijk L.J., van der Meer R.W., Jonker J.T. 2013. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PloS one, 8(3):e59697.
10. Halabis M, Dziedzic M, Warchulinska J, Kaznowska-Bystryk I, Solski J. 2015. Omentin-a new adipokine with many roles to play. Current Issues Pharmacy and Medical Sciences, 28(3):176-180.
11. Hoffmann J.G., Xie W., Chopra A.R. 2020. Energy regulation mechanism and therapeutic potential of asprosin. Diabetes, 69(4):559-566.
12. Hong T., Li J.Y., Wang Y.D., Qi X.Y., Liao Z.Z., Bhadel P. 2021. High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome. International Journal of Endocrinology, 2021:6622129.
13. Karbalamahdi A., Abedi B., Fatolahi H., Pazoki A. 2019. Effect of aerobic training and C. vulgaris intake on lipid profile and leptin in obese women. Hormozgan Medical Journal, 23(2):e91436-e.
14. Lad N., Murphy A.M., Parenti C., Williams N.C., Nelson C.P., Sharpe G.R., et al., editors. 2022. The effect of novel adipokine asprosin on mitochondrial function in human airway epithelial cells. Endocrine Abstracts; 2022:86
15. Lee H.S., Kim M.K. 2009. Effect of Chlorella vulgaris on glucose metabolism in Wistar rats fed high fat diet. Journal of Medicinal Food, 12(5):1029-1037.
16. Lee T., Yun S., Jeong J.H., Jung T.W. 2019. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Molecular and Cellular Endocrinology, 486:96-104.
17. Lestari P.H.P., Nurahmi N., Esa T., Kurniawan L.B. 2021. Omentin-1 Levels in Obesity. Indonesian Journal of Clinical Pathology and Medical Laboratory, 28(1):22-25.
18. Molaei Jeghanab M., Gholami M., Banaeifar A., Ghazalian F. 2022. The effect of eight weeks resistance training along with vitamin D consumption on levels of chemerin and omentin-1 in type 2 diabetic patients. Metabolism and Exercise, 2(2):129-149.
19. Moreno-Navarrete J.M., Catalán V., Ortega .F, Gómez-Ambrosi J., Ricart W., Frühbeck G. 2010. Circulating omentin concentration increases after weight loss. Nutrition and Metabolism, 7(1):1-6.
20. Nakhaei H., Nayebifar S., Fanaei H. 2022. Decrease in serum asprosin levels following six weeks of spinning and stationary cycling training in overweight women. Hormone Molecular Biology and Clinical Investigation. 44(1):21-26.
21. Noguchi N, Konishi F, Kumamoto S, Maruyama I, Ando Y, Yanagita T. 2013. Beneficial effects of Chlorella on glucose and lipid metabolism in obese rodents on a high-fat diet. Obesity Research and Clinical Practice, 7(2):e95-e105.
22. Ouerghi N, Fradj MKB, Duclos M, Bouassida A, Feki M, Weiss K, 2022. Effects of High-Intensity Interval Training on Selected Adipokines and Cardiometabolic Risk Markers in Normal-Weight and Overweight/Obese Young Males. A Pre-Post Test Trial. Biology, 11(6):853.
23. Pan H.Y., Guo L., Li Q. 2010. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Research and Clinical Practice, 88(1):29-33.
24. Panagiotou G., Triantafyllidou S., Tarlatzis B.C., Papakonstantinou E. 2021. Serum levels of irisin and omentin-1 in breast neoplasms and their association with tumor histology. International Journal of Endocrinology, 2021:6656671.
25. Pirani H., Roustaie M., Ravasi A.A., Lamir A.R. 2022. Effects of 8-week high-intensity interval training and continuous aerobic training on asprosin secretion and fibrillin-1 gene expression levels in diabetic male rats. International Journal of Diabetes in Developing Countries, 2022:1-6.
26. Rani K., Sandal N., Sahoo P. 2018. A comprehensive review on chlorella-its composition, health benefits, market and regulatory scenario. The Pharma Innovation Journal, 7(7):584-589.
27. Romere C., Duerrschmid C., Bournat J., Constable P., Jain M., Xia F. 2016. Asprosin, a fasting-induced glucogenic protein hormone. Cell, 165(3):566-579.
28. Sakurai T., Izawa T., Kizaki T., Ogasawara J.E., Shirato K., Imaizumi K., 2009. Exercise training decreases expression of inflammation-related adipokines through reduction of oxidative stress in rat white adipose tissue. Biochemical and Biophysical Research Communications, 379(2):605-609.
29. Salminen A., Kaarniranta K., Kauppinen A. 2016. Age-related changes in AMPK activation: role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways. Ageing Research Reviews, 28:15-26.
30. Sanayei M., Kalejahi P., Mahinkazemi M., Fathifar Z., Barzegar A. The effect of Chlorella vulgaris on obesity related metabolic disorders: a systematic review of randomized controlled trials. Journal of Complementary and Integrative Medicine, 19(4):833-842.
31. Sanayei M., Izadi A., Hajizadeh-sharafabad F, Amirsasan R, Kaviani M, Barzegar A. 2021. Chlorella vulgaris in combination with high intensity interval training in overweight and obese women: a randomized double-blind clinical trial. Journal of Diabetes and Metabolic Disorders, 2021:1-12.
32. Sanayei M., Izadi A., Hajizadeh-Sharafabad F., Amirsasan R., Kaviani M., Barzegar A. 2021. Chlorella vulgaris in combination with high intensity interval training in overweight and obese women: a randomized double-blind clinical trial. Journal of Diabetes and Metabolic Disorders, 20(1):781-792.
33. Schäffler A., Neumeier M., Herfarth H., Fürst A., Schölmerich J., Büchler C. 2005. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1732(1-3):96-102.
34. Shafeie A.A., Tahmasebi W., Azizi M. 2019. The simultaneous effects of Chlorella vulgaris supplementation and high intensity interval training on IL-6 serum levels reduction and insulin resistance on overweight men. Journal of Neishabour University of Medical Sciences,7(3):75-88.
35. Shibata S., Hayakawa K., Egashira Y., Sanada H. 2007. Hypocholesterolemic mechanism of Chlorella: Chlorella and its indigestible fraction enhance hepatic cholesterol catabolism through up-regulation of cholesterol 7α-hydroxylase in rats. Bioscience, Biotechnology, and Biochemistry, 71(4):916-925.
36. Strasser B., Schobersberger W. 2011. Evidence for resistance training as a treatment therapy in obesity. Journal of Obesity, 2011:482564.
37. Tan B.K., Adya R., Farhatullah S., Lewandowski K.C., O’Hare P., Lehnert H. 2008. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes, 57(4):801-808.
38. Ugur K., Erman F., Turkoglu S., Aydin Y., Aksoy A., Lale A. 2022. Asprosin, visfatin and subfatin as new biomarkers of obesity and metabolic syndrome. European Review for Medical and Pharmacological Sciences, 26(6):2124-2133.
39. Unamuno X., Gómez‐Ambrosi J., Rodríguez A., Becerril S., Frühbeck G., Catalán V. 2018. Adipokine dysregulation and adipose tissue inflammation in human obesity. European Journal of Clinical Investigation, 48(9):e12997.
40. Wang Y., Qu H., Xiong X., Qiu Y., Liao Y., Chen Y. 2018. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators of Inflammation, 2018:9471583.
41. Wang C.Y., Lin T.A., Liu K.H., Liao C.H., Liu Y.Y., Wu V.C. 2019. Serum asprosin levels and bariatric surgery outcomes in obese adults. International Journal of Obesity, 43(5):1019-1025.
42. Watanabe T., Watanabe‐Kominato K., Takahashi Y., Kojima M., Watanabe R. 2011. Adipose tissue‐derived omentin‐1 function and regulation. Comprehensive Physiology, 7(3):765-781.
43. Wilms B, Ernst B, Gerig R, Schultes B. 2015. Plasma omentin-1 levels are related to exercise performance in obese women and increase upon aerobic endurance training. Experimental and Clinical Endocrinology and Diabetes, 123(03):187-192.
44. Yamawaki H., Tsubaki N., Mukohda M., Okada M., Hara Y. 2010. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochemical and Biophysical Research Communications, 393(4):668-672.
45. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C. 2006. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. American Journal of physiology-endocrinology and Metabolism, 290(6):E1253-E1261.
46. Zabetian-Targhi F., Mirzaei K., Keshavarz S.A., Hossein-Nezhad A. 2016. Modulatory role of omentin-1 in inflammation: cytokines and dietary intake. Journal of the American College of Nutrition, 35(8):670-678.
47. Zatterale F., Longo M., Naderi J., Raciti G.A., Desiderio A., Miele C. 2020. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Frontiers in Physiology, 10:1607.
48. Zehsaz F., Farhangi N., Ghahramani M. 2016. The response of circulating omentin-1 concentration to 16-week exercise training in male children with obesity. The Physician and Sportsmedicine, 44(4):355-361.
49. Zengi S., Zengi O., Kirankaya A, Kucuk SH, Kutanis EE, Yigit O. 2019. Serum omentin-1 levels in obese children. Journal of Pediatric Endocrinology and Metabolism, 32(3):247-251.

Zhao A., Xiao H., Zhu Y., Liu S., Zhang S., Yang Z. 2022. Omentin-1: a newly discovered warrior against metabolic related diseases. Expert Opinion on Therapeutic Targets, 26(3):275-289.